文献速递浆细胞疾病造血干细胞移植与细胞治疗

回输CD34(+)细胞剂量对初诊多发性骨髓瘤自体移植造血重建及移植结局的影响

[Impact of the infused CD34(+) cell dose on hematopoietic reconstitution and transplant-related outcomes in newly diagnosed multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

该回顾性研究纳入57例初诊多发性骨髓瘤患者,按回输CD34(+)细胞剂量分为低剂量组(<4×10^6/kg,19例)和高剂量组(≥4×10^6/kg,38例)。结果显示高剂量组中性粒细胞和血小板植入更快,重度骨髓抑制和粒细胞缺乏伴发热持续时间更短,血小板输注需求更少,且PFS和OS更优。

要点

  • 回输CD34(+)细胞≥4×10^6/kg与更快的中性粒细胞和血小板植入相关。
  • 高剂量组重度骨髓抑制和粒细胞缺乏伴发热持续时间更短,血小板输注更少。
  • 高剂量组PFS和OS优于低剂量组,且可能与较低复发/进展风险独立相关。

核心结论

  • 初诊MM患者auto-PBSCT后回输CD34(+)细胞≥4×10^6/kg与更快造血重建、更短重度骨髓抑制及更少血小板输注相关,并可能改善长期生存。

研究设计与样本

  • 回顾性分析2020年7月27日至2025年8月29日在安徽医科大学第二附属医院首次接受auto-PBSCT的初诊MM患者57例。
  • 按回输CD34(+)细胞剂量分为低剂量组(<4×10^6/kg,n=19)和高剂量组(≥4×10^6/kg,n=38)。

主要发现

  • 高剂量组中性粒细胞植入时间中位数10.00 d vs 低剂量组11.00 d(P=0.014)。
  • 高剂量组血小板植入时间中位数10.00 d vs 低剂量组12.00 d(P=0.009)。
  • 高剂量组重度骨髓抑制持续时间更短、粒细胞缺乏伴发热持续时间更短、血小板输注量更少(P值均<0.05)。
  • 高剂量组中位PFS未达到 vs 低剂量组773 d(P=0.040),中位OS未达到 vs 812 d(P=0.009)。

关键数值与推荐

  • CD34(+)细胞回输剂量≥4×10^6/kg与10 d内中性粒细胞植入独立相关(OR=4.661,95% CI:1.322~16.435,P=0.017)。
  • ISS Ⅲ期与10 d内血小板植入受限独立相关(OR=0.217,95% CI:0.060~0.781,P=0.019)。
  • 移植前化疗次数增加与10 d内血小板植入受限独立相关(OR=0.706,95% CI:0.520~0.958,P=0.025)。
  • CD34(+)细胞回输剂量≥4×10^6/kg可能与较低复发/进展风险独立相关(HR=0.212,95% CI:0.052~0.870,P=0.031)。

临床怎么用

  • 初诊MM患者行auto-PBSCT时,可考虑将回输CD34(+)细胞剂量提升至≥4×10^6/kg以促进造血重建。
  • 对于ISS Ⅲ期或移植前化疗次数较多的患者,需关注血小板植入延迟风险。

局限性

  • 本研究为单中心回顾性分析,样本量57例,结论需前瞻性大样本研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the impact of different infused CD34(+) cell doses on hematopoietic reconstitution and transplant-related outcomes in patients with multiple myeloma (MM) undergoing autologous peripheral blood stem cell transplantation (auto-PBSCT) . Methods: We retrospectively analyzed 57 newly diagnosed MM patients who underwent first auto-PBSCT at the Second Affiliated Hospital of Anhui Medical University between July 27, 2020 and August 29, 2025. Patients were stratified by infused CD34(+) cell dose into a low-dose group (<4×10(6)/kg, n=19) and a high-dose group (≥4×10(6)/kg, n=38). The primary endpoints were time to neutrophil engraftment and time to platelet engraftment. Secondary endpoints included the duration of grade 3-4 neutropenia, duration of grade 3-4 thrombocytopenia, duration of febrile neutropenia, and platelet transfusion requirements. Secondary endpoints were adjusted for multiple comparisons using the Benjamini-Hochberg false discovery rate (FDR) procedure. Logistic regression was used to identify factors associated with neutrophil and platelet engraftment within 10 days. Survival outcomes, including progression-free survival (PFS) and overall survival (OS), were analyzed using the Kaplan-Meier method and Cox regression analysis. Results: The median infused CD34(+) cell dose was 5.30 (3.49, 9.35) ×10(6)/kg, and all patients achieved hematopoietic reconstitution. Compared with the low-dose group, the high-dose group had shorter time to neutrophil engraftment (median: 10.00 d vs 11.00 d, P=0.014) and platelet engraftment (median: 10.00 d vs 12.00 d, P=0.009). The high-dose group also had shorter duration of severe cytopenia, shorter febrile neutropenia duration, and lower platelet transfusion requirements (all P value<0.05). Multivariable analysis showed that an infused CD34(+) cell dose ≥4×10(6)/kg was independently associated with neutrophil engraftment within 10 days (OR=4.661, 95% CI: 1.322-16.435, P=0.017), whereas ISS stage Ⅲ (OR=0.217, 95% CI: 0.060-0.781, P=0.019) and a higher number of pre-transplant chemotherapy cycles (OR=0.706, 95% CI: 0.520-0.958, P=0.025) were associated with failure to achieve platelet engraftment within 10 days. Survival analysis showed that the high-dose group had superior PFS and OS compared with the low-dose group (median PFS time: not reached vs 773 d, P=0.040; median OS time: not reached vs 812 d, P=0.009), and that an infused CD34(+) cell dose ≥4×10(6)/kg might be independently associated with a lower risk of relapse or disease progression (HR=0.212, 95% CI: 0.052-0.870, P=0.031) . Conclusion: In patients with newly diagnosed MM undergoing auto-PBSCT, an infused CD34(+) cell dose ≥4×10(6)/kg was associated with faster neutrophil engraftment, shorter duration of severe myelosuppression, reduced time of febrile neutropenia, and decreased need for platelet transfusions, and may improve long-term survival outcomes. 目的: 探讨不同CD34(+)细胞回输剂量对多发性骨髓瘤(MM)患者自体外周血造血干细胞移植(auto-PBSCT)后造血重建及移植相关结局的影响。 方法: 回顾性纳入2020年7月27日至2025年8月29日在安徽医科大学第二附属医院首次接受auto-PBSCT的初诊MM患者57例。按回输CD34(+)细胞剂量分为低剂量组(<4×10(6)/kg,19例)与高剂量组(≥4×10(6)/kg,38例)。主要终点为中性粒细胞植入时间及血小板植入时间;次要终点为3~4级中性粒细胞减少及血小板减少持续时间、粒细胞缺乏伴发热持续时间及血小板输注量,并对次要终点进行Benjamini-Hochberg假发现率(FDR)校正。采用Logistic回归分析10 d内中性粒细胞及血小板植入的影响因素。生存结局采用Kaplan-Meier法及Cox回归分析。 结果: 57例患者回输CD34(+)细胞量中位数为5.30(3.49,9.35)×10(6)/kg,均获得造血重建。与低剂量组相比,高剂量组中性粒细胞植入时间(中位数:10.00 d对11.00 d,P=0.014)及血小板植入时间(中位数:10.00 d对12.00 d,P=0.009)更短;重度骨髓抑制持续时间更短、粒细胞缺乏伴发热持续时间更短、血小板输注量更少(P值均<0.05)。多因素分析显示,CD34(+)细胞回输剂量≥4×10(6)/kg与10 d内中性粒细胞植入独立相关(OR=4.661,95% CI:1.322~16.435,P=0.017);国际分期系统(ISS)Ⅲ期(OR=0.217,95% CI:0.060~0.781,P=0.019)及移植前化疗次数增加(OR=0.706,95% CI:0.520~0.958,P=0.025)与10 d内血小板植入受限独立相关。生存分析显示,高剂量组无进展生存(PFS)及总生存(OS)优于低剂量组(中位PFS期:未达到对773 d,P=0.040;中位OS期:未达到对812 d,P=0.009),且CD34(+)细胞回输剂量≥4×10(6)/kg可能与较低的复发/进展风险独立相关(HR=0.212,95% CI:0.052~0.870,P=0.031)。 结论: 初诊MM患者auto-PBSCT后CD34(+)细胞回输剂量≥4×10(6)/kg与更快的中性粒细胞植入、更短的重度骨髓抑制持续时间和粒细胞缺乏伴发热时间及更少的血小板输注需求相关,并可能改善长期生存预后。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Xie BB, An FR, Zhang LL, et al. [Impact of the infused CD34(+) cell dose on hematopoietic reconstitution and transplant-related outcomes in newly diagnosed multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42706157. doi:10.3760/cma.j.cn121090-20260118-00035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。